1. Home
  2. DCTH vs PRCH Comparison

DCTH vs PRCH Comparison

Compare DCTH & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • PRCH
  • Stock Information
  • Founded
  • DCTH 1988
  • PRCH 2012
  • Country
  • DCTH United States
  • PRCH United States
  • Employees
  • DCTH N/A
  • PRCH N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • PRCH Computer Software: Prepackaged Software
  • Sector
  • DCTH Health Care
  • PRCH Technology
  • Exchange
  • DCTH Nasdaq
  • PRCH Nasdaq
  • Market Cap
  • DCTH 630.4M
  • PRCH 656.3M
  • IPO Year
  • DCTH N/A
  • PRCH N/A
  • Fundamental
  • Price
  • DCTH $12.76
  • PRCH $12.20
  • Analyst Decision
  • DCTH Strong Buy
  • PRCH Strong Buy
  • Analyst Count
  • DCTH 4
  • PRCH 8
  • Target Price
  • DCTH $24.00
  • PRCH $9.66
  • AVG Volume (30 Days)
  • DCTH 748.0K
  • PRCH 2.2M
  • Earning Date
  • DCTH 08-04-2025
  • PRCH 08-05-2025
  • Dividend Yield
  • DCTH N/A
  • PRCH N/A
  • EPS Growth
  • DCTH N/A
  • PRCH N/A
  • EPS
  • DCTH N/A
  • PRCH N/A
  • Revenue
  • DCTH $53,850,000.00
  • PRCH $427,150,000.00
  • Revenue This Year
  • DCTH $155.42
  • PRCH $4.28
  • Revenue Next Year
  • DCTH $37.93
  • PRCH $12.88
  • P/E Ratio
  • DCTH N/A
  • PRCH N/A
  • Revenue Growth
  • DCTH 1068.87
  • PRCH N/A
  • 52 Week Low
  • DCTH $7.17
  • PRCH $1.05
  • 52 Week High
  • DCTH $18.23
  • PRCH $12.83
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 32.99
  • PRCH 67.10
  • Support Level
  • DCTH $13.30
  • PRCH $10.55
  • Resistance Level
  • DCTH $14.15
  • PRCH $12.09
  • Average True Range (ATR)
  • DCTH 0.66
  • PRCH 0.71
  • MACD
  • DCTH -0.27
  • PRCH 0.04
  • Stochastic Oscillator
  • DCTH 2.91
  • PRCH 84.77

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.

Share on Social Networks: